ASS1 and breast carcinoma: ASS1-expressing cells, such as the breast cancer cell line MDAMB468 (Fig. 5A and J) or the osteosarcoma cell line MG63, did not respond in a meaningful way to dual treatment with ADI-PEG20 and A1331852 (Fig. 5A and K).